Glutamatergic augmentation strategies for cognitive impairment in schizophrenia

Psychiatric Annals

Volumn 29, Issue 11, 1999, Pages 649-654

  Goff, Donald C ^a   Bagnell, Alexa L ^b   Perlis, Roy H ^b  

^a Freedom Trail Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033463523     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19991101-11     Document Type: Article

References (48)

1. Huntley GW, Vickers JC, Morrison JH. Cellular and synaptic localization of NMDA and non-NMDA receptor subunits in neocortex: organizational features related to cortical circuitry, function and disease. Trends Neurosci. 1994;17:536-543.
2. McEntee W, Crook T. Glutamate: its role in learning, memory, and the aging brain. Psychopharmacology. 1993;111:391-401.
3. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-634.
4. Huettner JE. Competitive antagonism of glycine at the N-methyl-D-aspartate (NMDA) receptor. Biochem Pharmacol. 1991;41:9-16.
5. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
6. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry. 1996;3:241-253.
7. Goff D, Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophr Res. 1997;27:157-168.
8. Eastwood SL, McDonald B, Burnet PWJ, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Molecular Brain Research. 1995;29:211-223.
9. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet. 1991;337:450-452.
10. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience. 1990;39:25-32.
11. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci. 1996;16:19-30.
12. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 1995;674:82-90.
13. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci. 1995;15:2453-2461.
14. Sokolov B. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of "neuroleptic-free" schizophrenics: evidence on reversible up-regulation by typical neuroleptics. J Neurochem. 1998;71:2454-2464.
15. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52:829-836.
16. Sekiguchi M, Okamoto K, Sakai Y. N-acetylaspartyl glutamate suppresses the climbing fiber response of Purkinje cells in guinea pigs' cerebellar slices and the responses to excitatory amino acids of Xenopus laevis oocytes injected with cerebellar mRNA. Brain Res. 1989;482:87-96.
17. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301-1308.
18. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R. Study of a new schizophrenomimetic drug: sernyl. Archives of Neurology and Psychiatry. 1959;81:363-369.
19. Jentsch J, Roth R. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20:201-225.
20. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
21. Malhotra A, Pinals D, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology. 1996; 14:301-307.
22. Malhotra A, Pinals D, Adler C, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology. 1997;17:141-150.
23. Jentsch J, Redmond DJ, Elsworth J, Taylor J, Youngren K, Roth R. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science. 1997;277:953-955.
24. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921-2927.
25. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology. 1995;13:9-19.
26. Malhotra A, Adler C, Kennison S, Elman I, Pickar D, Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42:664-668.
27. Bakshi V, Swedlow N, Geyer M. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic drug olanzapine. Psychopharmacology. 1995;122:198-201.
28. Bakshi VP, Swerdlow NR, Geyer MA. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther. 1994;271:787-794.
29. Swerdlow N, Bakshi V, Geyer M. Seroquel restores sensorimotor gating in phencyclidine-treated rats. J Pharmacol Exp Ther. 1996;279:1290-1299.
30. Lawlor BA, Davis KL. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease? Biol Psychiatry. 1992;31:337-350.
31. D'Souza DC, Charney D, Krystal J. Glycine site agonists of the NMDA receptor: a review. CNS Drug Reviews. 1995;1:227-260.
32. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatmentresistant schizophrenia. Br J Psychiatry. 1996;169:610-617.
33. Javitt DC, Zylberman I, Zukin SR, Heresco LU, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994;151:1234-1236.
34. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999;56:29-36.
35. Tsai G, Yang P, Chung L-C, Lange N, Coyle J. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998;44:1081-1089.
36. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res. 1990;510:158-160.
37. Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995;152:1213-1215.
38. Sternberg S. High-speed scanning in human memory. Science. 1996;153:652-654.
39. Goff D, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999; 56:21-27.
40. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257:7-12.
41. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628-1630.
42. Goff D, Henderson D, Evins A, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999; 45:512-514.
43. Arai A, Kessler M, Rogers G, Lynch G. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor currents and synaptic transmission in hippocampus. J Pharmacol Exp Ther. 1996;278:1-12.
44. Sirvio J, Larson J, Quach L, Rogers G, Lynch G. Effects of pharmacologically facilitating glutamatergic transmission in the trisynaptic intrahippocampal circuit. Neuroscience. 1996;74:1025-1035.
45. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory. Proc Natl Acad Sci U S A. 1994;91:777-781.
46. Johnson S, Luu N, Herbst T, et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther. 1999;289:392-397.
47. Goff D, Berman I, Posever T, Leahy L, Lynch G. Ampakine (CX516) added to clozapine in schizophrenia: preliminary safety and efficacy data. Presented at the annual meeting of the American College of Neuropsychopharmacology; Puerto Rico; December 15, 1998.
48. Goff D, Berman I, Posever T, Herz L, Leahy L, Lynch G. A preliminary dose escalation trial of CX516 (AMPAKINE) added to clozapine in schizophrenia. Schizophr Res. 1999;36:280.